Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
- J. Bussel, D. Kuter, +11 authors J. Nichol
- The New England journal of medicine
- 19 October 2006
AMG 531 caused no major adverse events and increased platelet counts in patients with ITP, and increases in the platelet count were dose-dependent. Expand
Camphor intoxication treated by resin hemoperfusion.
In the course of treating a patient who had ingested camphorated oil, hemoperfusion through amberlite resin was used and shown to be a new, effective, and less cumbersome therapeutic modality. Expand
Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.
Individualized weekly doses of AMG 531 may provide a therapeutic option in ITP, potentially enabling patients to taper off long-term corticosteroid therapy and has been generally well tolerated in this ongoing study. Expand
Effects of Two New Dissociative Anesthetic Agents, Ketamine and CL‐1848C, on the Respiratory Response to Carbon Dioxide
The term “dissociative anesthesia” was used to describe the anesthetic state characteristic of both drugs, and ketamine acts rapidly, on intravenous or intramuscular administration, to produce a state characterized by catalepsy, analgesia, and amnesia. Expand
A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune…
AMG531 was well tolerated and both doses were able to increase plt cts within the targeted range, and response variability suggests that individual dose adjustment will be required to achieve the desired outcome. Expand
Safety Profile of AMG 531 in Healthy Volunteers and in Thrombocytopenic Patients with Immune Thromobocytopenic Purpura.
- D. Stepan, E. Sergis-Deavenport, R. Kelly, J. Christal, Chien-Feng Chen, J. Nichol
- 16 November 2005
Results suggest that both unit dosing and weight-based dosing provide a predictable platelet response in healthy volunteers and ITP patients and AMG 531 may represent a new treatment option for thrombocytopenic patients with ITP. Expand
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.
AMG 531 was well-tolerated, and effectively increased and sustained platelet counts in splenectomized patients with ITP, and were able to reduce their use of concurrent therapies. Expand
Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies
AMG 531 appeared to be well-tolerated in ITP pts and reduced the incidence of bleeding events among pts exhibiting a platelet response, as reported in both S and NS patients. Expand
The effect of treatment with a new antidepressant: INN 00835 on platelet serotonin uptake in depressed patients
- B. Leonard, G. Nicolau, +5 authors J. Noble
- Medicine, Psychology
- European Neuropsychopharmacology
- 1 November 1998
The data tend to substantiate the use of platelet serotonin uptake as a biochemical marker of effective treatment of depression. Expand
Modern Practical Neurology: An Introduction to Diagnosis and Management of Common Neurologic Disorders—2nd ed
- R. Kelly
- 1 June 1982
the persistent long-term effects of selective monoamine oxidase inhibitors, and interesting studies on the possibility of producing a reversible MAO inhibitor with high affinity for the type A… Expand